Floatz logo

Voxelotor

Sickle Cell Nephropathy

University of Illinois at ChicagoSmall moleculePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

135 Active assets in the Sickle Cell Nephropathy cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 4BB
MAGNESIUM METALLICUM
Medical College of Wisconsin
Phase 3BB

View all 50 →

Same molecule, other indications

Voxelotor is also rated in:

sickle cell diseaseDormant
B
Indicative ·
57 / 100
View asset →
ulcer of lower limbsDormant
CCC
Indicative ·
48 / 100
View asset →
idiopathic pulmonary fibrosisDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →